Tag - SAVA

Developments

Cassava Sciences reports additional data from Phase 2b Alzheimer’s disease trial

Cassava Sciences (NASDAQ:SAVA) reported additional data from its Phase 2b study of sumifilam for the treatment of Alzheimer’s disease (AD). The study enrolled 64 patients with mild-to-moderate AD, 50-to-85 years of age...

November 4, 2020

Developments

Cassava Sciences PTI-125 fails Phase 2b Alzheimer’s disease study

Cassava Sciences (NASDAQ:SAVA) reported disappointing topline results from its Phase 2b study of PTI-125 for the treatment of Alzheimer’s disease (AD). The study enrolled 64 patients with mild-to-moderate AD, 50-to-85...

May 15, 2020

Markets

Maxim ups Cassava Sciences PT to $12 from $3

Maxim Group raised its price target for Cassava Sciences (NASDAQ:SAVA) to $12 from $3, citing the recent rise in the company’s share price. The stock closed at $7.93 on Jan. 9. “Cassava’s shares have risen significantly...

January 10, 2020

Tag - SAVA

Cassava Sciences reports additional data from Phase 2b Alzheimer’s disease trial

Cassava Sciences PTI-125 fails Phase 2b Alzheimer’s disease study

Maxim ups Cassava Sciences PT to $12 from $3

General

More